Study Information
| Title: | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib  |
| Status: | Recruiting participants |
| Conditions: | Hepatocellular Carcinoma |
| Interventions: | Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B) |
| Health Topics: | Liver Cancer |
Contact Information
ImClone Investigational Site
Boston, MA 02111
ImClone Investigational Site
Boston, MA 02114
ImClone Investigational Site
Worcester, MA 01605